Brief: VBL Therapeutics Announces Completion Of Enrollment In Oval Phase 3 Trial Of Ofra-Vec
08/03/2022 13:16
March 8 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN OVAL PHASE 3
REGISTRATION-ENABLING TRIAL OF OFRA-VEC IN OVARIAN CANCER AND UNANIMOUS
RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING COMMITTEE TO CONTINUE STUDY
AS PLANNED
Source text for Eikon: ID:nGNX9y7sFR
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives